Use of Methadone for Cancer Pain Management in a Tertiary Cancer Care Centre: A Retrospective Observational Cohort Study
Journal of Onco-Anaesthesiology and Perioperative Medicine · 2026-01 · 3 (1) · 53-59
DOI: 10.4103/joapm.joapm_52_25 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Onco-Anaesthesiology and Perioperative Medicine, online erschienen am 10.03.2026. Verfasst von Priya Chowdhury und 5 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Schmerzmanagement, Onkologische Pflege
Abstract (Originalsprache)
Background and Aims: Cancer pain significantly impacts patient well-being, with a high prevalence in India. While the World Health Organisation pain ladder is effective, a substantial proportion of patients experience opioid-refractory pain. Methadone, with its unique multi-modal analgesic mechanisms such as mu-receptor agonism, N-Methyl-D-Aspartate antagonism and serotonin/norepinephrine reuptake inhibition, offers a valuable option for such cases, despite its variable pharmacokinetics and potential for adverse effects, such as corrected QT (QTc) prolongation.
Methods
This retrospective audit was conducted on a prospectively maintained database of 29 adult cancer patients with chronic pain who received methadone at a tertiary cancer care centre in India from March 2023 to June 2024. Demographics, pain severity (numeric rating scale, [NRS]), prior opioid use, methadone dosing regimens and reported adverse effects were collected. Institutional Review Board approval was obtained, with a waiver of individual consent.
Results
At methadone initiation, 27 out of 29 patients reported severe pain (NRS 7-10). The majority had a neuropathic pain component. Twenty-seven patients were on strong opioids, of whom 22 were switched to methadone due to inadequate pain control. Methadone was most commonly started at 15–20 mg/day, at 6 to 8 hourly intervals. Two out of 28 patients who came for the first follow-up after initiation of methadone reported severe pain, resulting in a meaningful reduction in severe pain prevalence. By the second follow-up, attrition of 8 of 29 patients was noted, attributable to disease progression, inability to report to the pain clinic due to functional decline and death. One patient developed QTc prolongation (>463 ms) at 45 mg/day. Constipation was the most commonly reported adverse effect, resulting in a few discontinuations.
Conclusion
Methadone is effective for refractory cancer pain. Its use requires cautious initiation and titration due to inter-individual variability and adverse effects like QTc prolongation. This audit highlights methadone’s utility in a real-world clinical setting.
Zitieren
APA
Chowdhury, P., Nandi, R., Barman, S. M., More, S., Goswami, J., & Kundu, S. (2026). Use of Methadone for Cancer Pain Management in a Tertiary Cancer Care Centre: A Retrospective Observational Cohort Study. Journal of Onco-Anaesthesiology and Perioperative Medicine, 3(1), 53-59. https://doi.org/10.4103/joapm.joapm_52_25
Vancouver
Chowdhury P, Nandi R, Barman SM, More S, Goswami J, Kundu S. Use of Methadone for Cancer Pain Management in a Tertiary Cancer Care Centre: A Retrospective Observational Cohort Study. Journal of Onco-Anaesthesiology and Perioperative Medicine. 2026;3(1):53-59. doi:10.4103/joapm.joapm_52_25
BibTeX
@article{Chowdhury2026,
author = {Chowdhury, Priya and Nandi, Rudranil and Barman, Suparna Mitra and More, Shikhar and Goswami, Jyotsna and Kundu, Sudipta},
title = {Use of Methadone for Cancer Pain Management in a Tertiary Cancer Care Centre: A Retrospective Observational Cohort Study},
journal = {Journal of Onco-Anaesthesiology and Perioperative Medicine},
year = {2026},
volume = {3},
number = {1},
pages = {53--59},
doi = {10.4103/joapm.joapm_52_25}
}
EUVIMED